- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
Setting: Hospital
Encompassing all units and departments within a hospital setting
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Emergency department
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Vaccination
- Arexvy
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Emergency department
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Fragile population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Palivizumab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Vaccination
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Blood sample
- Adults (18-64 years)
- Pregnant women
- Hospital
- Outpatient clinic
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Vaccination
- Nirsevimab
- Abrysvo
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Blood sample
- Nasopharyngeal swab
- Nasal lining fluid sample
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Human metapneumovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Human metapneumovirus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Non-hospital health centre
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Metapneumovirus
- Parainfluenza Virus
- Rhinovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Adenovirus infection
- Metapneumovirus infection
- Parainfluenza virus infection
- Rhinovirus infection